CTI is ready to help with your next drug development project
Regenerative Medicine / Gene Therapy is a unique and growing area of research. CTI is a leader in regenerative medicine drug and device development. We understand the specific challenges these projects present, including regulatory hurdles, complex logistics around biological sample collection, shipment, and implantation, as well as complicated site training requirements based on unique cell and gene technologies. Our experience includes both autologous and allogeneic stem cells as well as other cell/gene interventions. We work with innovators, key opinion leaders, cutting edge biotechnology/pharmaceutical companies, and investigators on our ongoing programs, as well as participate in industry groups such as the Alliance for Regenerative Medicine (ARM). We are committed to the advancement of important, life-changing therapies, and we support innovation by sponsoring and speaking at industry meetings such as Stem Cell on the Mesa, RegenMed Investor Day, and the Advanced Therapies Summit.
Mucopolysaccharidosis type IIIA (MPSIIIA)